John Crowley

John Crowley transformed from concerned father to pioneering biotechnology leader when his children were diagnosed with Pompe Disease, a rare genetic disorder. Rather than accepting their prognosis, he dedicated his career to developing life-saving treatments that could give his family hope.

As Chairman and CEO of Amicus Therapeutics, Crowley has built his company into a force for change in the rare disease space, proving that personal motivation can drive extraordinary scientific breakthroughs. Crowley's leadership exemplifies how individual determination can reshape entire industries.

His journey from parent facing an impossible diagnosis to biotechnology executive has created pathways for treatment that extend far beyond his own family. Through Amicus Therapeutics, he has demonstrated that innovative drug development can emerge from the most personal of challenges, ultimately saving lives and providing hope for countless families confronting rare genetic diseases.